Hantavirus and Ebola Headlines Put Healthcare Stocks Back in Focus
Hantavirus and Ebola Headlines Put Healthcare Stocks Back in Focus

Hantavirus and Ebola Headlines Put Healthcare Stocks Back in Focus

Thu, May 28, 2026 8:34 AM

Three deaths on a cruise ship. A WHO emergency declaration. And within days, Malaysia’s glove counters were among the market’s most actively traded stocks again.

It sounds familiar – because it is. Whenever a global health scare makes headlines, investors instinctively reach for the same playbook: buy gloves, watch the Healthcare Index, and wonder if this is the next COVID-19. Most of the time, it isn’t. But that doesn’t mean there’s nothing worth paying attention to.

What Triggered the Move

The Andes strain of hantavirus, linked to an outbreak aboard a cruise ship off South America in April 2026, resulted in three deaths and prompted emergency monitoring across more than 20 countries. Days later, the WHO declared the Ebola outbreak in Uganda and the DRC a public health emergency of international concern on May 17 – two unrelated outbreaks arriving in close succession, amplifying global health anxiety and triggering a swift market response.

Malaysia has no confirmed cases of either virus. The Health Ministry raised alert levels at all international entry points as a precautionary measure.

The reaction is not surprising. During periods of global health uncertainty, glove stocks are often treated by investors as “defensive trading proxies” due to Malaysia’s position as one of the world’s largest glove manufacturing hubs. This creates a familiar pattern where healthcare headlines quickly translate into speculative trading activity in glove counters.

What the Market Did

Between May 8 and May 12, Malaysia big four glove makers surged.

  • Top Glove (TOPGLOV, 7113) gained up to 13% over the period. On May 8, the first day of the rally, it was the most actively traded stock on Bursa Malaysia with over 91 million shares changing hands.
  • Hartalega (HARTA, 5168) and Supermax (SUPERMX, 7106) each rose up to 11%, while
  • Kossan (KOSSAN, 7153) gained 7%.

The Bursa Healthcare Index rose nearly 4% on May 12 – while the FBM KLCI fell 0.16% on the same day.

The move was largely sentiment driven. But it wasn’t purely noise either. Glove makers are entering this period of heightened attention with an already-improving earnings landscape – average selling price for nitrile gloves have recovered to around USD29 per 1,000 pieces, up from approximately USD16 a year earlier, a sign that industry pricing pressure may have bottomed after several challenging post-pandemic years.

Still, the current situation differs significantly from the COVID-19 pandemic period. There are no widespread lockdowns, demand shocks or supply disruptions at this stage. Instead, the recent rally reflects how sensitive glove stocks remain to global health headlines, particularly after a prolonged earnings recovery phase.

As Kenny Yee, Head of Research at Rakuten Trade, puts it: “Healthcare stocks, especially glove makers, tend to attract attention during periods of global health uncertainty. However, investors should differentiate between short-term sentiment driven movements and longer-term earnings sustainability.”

The Bigger  Picture

Here’s what often gets missed in the headline chase: Malaysia’s healthcare sector has a story that has nothing to do with outbreaks.

  • IHH Healthcare (IHH, 5225), Asia's largest private hospital group operating across 10 countries, reported 1QFY2026 net profit rising 3% year-on-year to RM528 million, with revenue growing 4% to RM6.55 billion. Growth was driven by higher inpatient and daycase volumes, a greater number of complex cases treated, and stronger contributions from Malaysia, Turkey and Europe. Core net profit grew 5% year-on-year to RM545 million, reflecting the underlying strength of the business. Rakuten Trade Research has a target price of RM10.17 on the stock.
  • Sunway Healthcare (SUNMED, 5555), one of the most talked-about listings of 2026, just posted 1QFY2026 revenue growth of 23.8% year-on-year to RM587 million. Foreign patient revenue surged 47% — driven by patients from Indonesia, China and Cambodia — underscoring Malaysia's growing influence as a medical tourism destination. Rakuten Trade Research has a target price of RM1.87.
  • KPJ Healthcare (KPJ, 5878), Malaysia’s largest domestic private hospital group, recorded surgical cases rising 11% and average revenue per inpatient up 7% in its latest results, with plans to add 2,200 new beds by 2030.

These aren't outbreak plays. They're fundamental growth stories – powered by an ageing population, rising healthcare spending and a medical tourism industry that continues to draw patients from across the region.

What This Means for You

Outbreak headlines are a prompt, not a strategy. They draw attention to a sector that was already worth watching — and occasionally create entry points worth considering. But the investors who do well in healthcare over the long run aren't the ones chasing virus headlines. They're the ones who understand the fundamentals before the headlines appear.

This article is for educational and informational purposes only and does not constitute investment advice. Stay updated with market insights and trending sector developments through Rakuten Trade's platforms and research updates.